Citizens JMP analyst Jason Butler initiated coverage of Achieve Life Sciences (ACHV) with an Outperform rating and $19 price target Achieve is developing cytisinicline, a nicotine dependence treatment for smoking cessation in adults, the analyst tells investors in a research note. The firm believes cytisinicline has a “highly differentiated” profile to Chantix and can both supplant and grow the current market.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHV:
- Promising Developments and Strategic Advancements Drive Positive Outlook for Achieve Life Sciences
- Positive Outlook for Achieve Life Sciences: Buy Rating Backed by Promising Regulatory Progress and Market Potential
- Achieve Life Sciences Reports Q3 2025 Results
- Achieve Life Sciences: Key Insights from Earnings Call
- Achieve Life Sciences: Advancements in Cytisinicline Propel Buy Rating Amid Regulatory Milestones and Clinical Success